

Supplementary file

Table S1. Studies included in the review.

Reference	Location	Number of Women Number of Men	Total Sample	Proportion of Women
[1] Kane et al. 2020a	North America	121 368	489	24.7%
[2] Cheng et al. 2019	Asia	286 283	569	50.3%
[3] Jena et al. 2019	Asia	43 58	101	42.6%
[4] Pu et al. 2019	Asia	50 33	83	60.2%
[5] Chen et al. 2018a	Asia	40 71	111	36.0%
[6] Gomez-revuelta et al. 2018	Europe	94 108	202	46.5%
[7] Schennach et al. 2018	Europe	49 63	112	43.8%
[8] Huang et al. 2017	Asia	20 37	57	35.1%
[9] Ismail et al. 2017	More than one continent	71 269	340	20.9%
[10] Citrome et al. 2016	Only USA	28 69	97	28.9%
[11] Grunder et al. 2016	Europe	44 92	136	32.4%
[12] Landbloom et al. 2016	More than one continent	148 209	357	41.5%
[13] Lieberman et al. 2016a	Only USA	58 276	334	17.4%
[14] Litman et al. 2016	Only USA	29 115	144	20.1%
[15] Malla et al. 2016	North America	16 69	85	18.8%
[16] Nasser et al. 2016	More than one continent	79 258	337	23.4%
[17] Parabiaghi et al. 2016	Europe	125 175	300	41.7%
[18] Buckley et al. 2015	Only USA	87 218	305	28.5%
[19] Ishigooka et al. 2015a	Asia	168 277	445	37.8%
[20] Meltzer et al. 2015a	More than one continent	200 423	623	32.1%
[21] Moosavi et al. 2015	Asia	15 75	90	16.7%
[22] Naber et al. 2015	More than one continent	113 168	281	40.2%
[23] Robinson et al. 2015	North America	58 140	198	29.3%
[24] Subotnik et al. 2015	Only USA	18 65	83	21.7%
[25] Tybura et al. 2015	Europe	102 89	191	53.4%
[26] Durgam et al. 2014	More than one continent	230 502	732	31.4%
[27] Hatta et al. 2014a	Asia	86 70	156	55.1%
[28] Li et al. 2014a	Asia	134 145	279	48.0%
[29] Mirabzadeh et al. 2014	Asia	0 66	66	0.0%
[30] Shen et al. 2014	More than one continent	80 209	289	27.7%
[31] Shoja et al. 2014	Asia	60 0	60	100.0%
[32] Amr et al. 2013	Asia	27 46	73	37.0%
[33] Wang et al. 2013	Asia	26 331	357	7.3%
[34] Chung et al. 2012	Asia	30 61	91	33.0%
[35] Jindal et al. 2012	Asia	26 34	60	43.3%
[36] Kane et al. 2012b	More than one continent	162 241	403	40.2%
[37] Kwon et al. 2012	Asia	177 212	389	45.5%
[38] Li et al. 2012b	Asia	66 53	119	55.5%
[39] Pawar et al. 2012	Asia	29 35	64	45.3%
[40] Witte et al. 2012	More than one continent	119 285	404	29.5%
[41] Grootens et al. 2011	Europe	13 61	74	17.6%
[42] Harvey et al. 2011a	Only USA	89 212	301	29.6%
[43] Li et al. 2011c	Asia	271 181	452	60.0%
[44] Meltzer et al. 2011b	More than one continent	104 369	473	22.0%
[45] Shah et al. 2011	Asia	76 138	214	35.5%
[46] Xiang et al. 2011	Asia	202 172	374	54.0%

[47]	Zhang et al. 2011	Asia	120 119	239	50.2%
[48]	Bhowmick et al. 2010	Asia	38 42	80	47.5%
[49]	Chen et al. 2010b	Asia	98 80	178	55.1%
[50]	Gaebel et al. 2010a	More than one continent	280 386	666	42.0%
[51]	Johnsen et al. 2010	Europe	69 144	213	32.4%
[52]	MacFadden et al. 2010	More than one continent	139 210	349	39.8%
[53]	Pandina et al. 2010	More than one continent	513 701	1214	42.3%
[54]	Roberts et al. 2010	Only USA	69 154	223	30.9%
[55]	Fleischhacker et al. 2009	More than one continent	304 399	703	43.2%
[56]	Hatta et al. 2009b	Asia	47 33	80	58.8%
[57]	Lublin et al. 2009	More than one continent	140 153	293	47.8%
[58]	Oliveira et al. 2009	Latin America	45 54	99	45.5%
[59]	Cutler et al. 2008a	More than one continent	121 472	593	20.4%
[60]	Jerrell et al. 2008	Only USA	39 68	107	36.4%
[61]	Kahn et al. 2008	More than one continent	200 298	498	40.2%
[62]	Kolotkin et al. 2008	Europe	219 322	541	40.5%
[63]	Nimwegen et al. 2008	Europe	26 102	128	20.3%
[64]	Sacchetti et al. 2008	Europe	33 42	75	44.0%
[65]	Safa et al. 2008	Asia	31 32	63	49.2%
[66]	Dossenbach et al. 2007a	More than one continent	32 91	123	26.0%
[67]	Goldberg et al. 2007	Not reported	79 109	188	42.0%
[68]	Kane et al. 2007c	More than one continent	301 327	628	47.9%
[69]	Marder et al. 2007a	Only USA	115 329	444	25.9%
[70]	McEvoy et al. 2007	Not reported	94 326	420	22.4%
[71]	Zimbroff et al. 2007	Only USA	84 169	253	33.2%
[72]	Azarin et al. 2006	Europe	73 113	186	39.2%
[73]	Cutler et al. 2006b	North America	79 288	367	21.5%
[74]	Harvey et al. 2006b	Not reported	67 222	289	23.2%
[75]	Harvey et al. 2006c	Not reported	25 47	72	34.7%
[76]	Kinon et al. 2006a	Not reported	118 228	346	34.1%
[77]	Lecrubier et al. 2006	Not reported	78 166	244	32.0%
[78]	McCue et al. 2006	Not reported	121 198	319	37.9%
[79]	Brook et al. 2005a	Not reported	190 377	567	33.5%
[80]	Chue et al. 2005	More than one continent	226 414	640	35.3%
[81]	Lieberman et al. 2005b	Only USA	380 1080	1460	26.0%
[82]	Schooler et al. 2005	More than one continent	159 396	555	28.6%
[83]	Strakowski et al. 2005	More than one continent	39 156	195	20.0%
[84]	Addington et al. 2004	More than one continent	81 215	296	27.4%
[85]	Appelper et al. 2004	Europe	20 30	50	40.0%
[86]	Corrigan et al. 2004	More than one continent	160 307	467	34.3%
[87]	Currier et al. 2004	Only USA	57 105	162	35.2%
[88]	Daniel et al. 2004a	Only USA	35 271	306	11.4%
[89]	Dossenbach et al. 2004b	Europe	32 28	60	53.3%
[90]	Gaebel et al. 2004b	Europe	60 80	140	42.9%
[91]	Harrigan et al. 2004	Not reported	44 139	183	24.0%
[92]	Kinon et al. 2004b	Not reported	30 70	100	30.0%
[93]	Knegtering et al. 2004	Not reported	15 36	51	29.4%
[94]	Mari et al. 2004	Latin America	43 154	197	21.8%
[95]	McQuade et al. 2004	More than one continent	88 229	317	27.8%
[96]	Mortimer et al. 2004	More than one continent	132 245	377	35.0%
[97]	Simpson et al. 2004	Not reported	93 176	269	34.6%
[98]	Yamashita et al. 2004	Asia	44 48	92	47.8%
[99]	Beasley et al. 2003a	More than one continent	153 173	326	46.9%

[100] Gureje et al. 2003	Oceania	27 38	65	41.5%
[101] Harvey et al. 2003d	Not reported	122 54	176	69.3%
[102] Hertling et al. 2003	Europe	54 90	144	37.5%
[103] Kane et al. 2003d	Only USA	100 300	400	25.0%
[104] Kasper et al. 2003	More than one continent	536 758	1294	41.4%
[105] Lieberman et al. 2003c	North America	48 215	263	18.3%
[106] Pigott et al. 2003	More than one continent	136 174	310	43.9%
[107] Potkin et al. 2003	Only USA	121 283	404	30.0%
[108] Ritchie et al. 2003	Oceania	47 19	66	71.2%
[109] Wright et al. 2003	More than one continent	107 204	311	34.4%
[110] Arato et al. 2002	Europe	80 214	294	27.2%
[111] Breier et al. 2002	More than one continent	115 155	270	42.6%
[112] Csernansky et al. 2002	Only USA	110 255	365	30.1%
[113] Hirsch et al. 2002	Not reported	104 197	301	34.6%
[114] Kane et al. 2002e	Only USA	126 288	414	30.4%
[115] Lee et al. 2002	Not reported	54 54	108	50.0%
[116] Sechter et al. 2002	Europe	140 170	310	45.2%
[117] Conley et al. 2001	Only USA	103 274	377	27.3%
[118] Daniel et al. 2001b	Only USA	15 64	79	19.0%
[119] Ishigooka et al. 2001b	Asia	61 113	174	35.1%
[120] Lessem et al. 2001	Only USA	39 78	117	33.3%
[121] Bouchard et al. 2000	North America	56 119	175	32.0%
[122] Brook et al. 2000b	More than one continent	9 123	132	6.8%
[123] Copolov et al. 2000	More than one continent	143 305	448	31.9%
[124] Emsley et al. 2000a	More than one continent	85 203	288	29.5%
[125] Heck et al. 2000	Europe	39 38	77	50.6%
[126] Purdon et al. 2000	Not reported	20 45	65	30.8%
[127] Daniel et al. 1999c	North America	87 215	302	28.8%
[128] Emsley et al. 1999b	More than one continent	61 122	183	33.3%
[129] Peuskens et al. 1999a	Europe	91 137	228	39.9%
[130] Goff et al. 1998	Only USA	6 84	90	6.7%
[131] Keck et al. 1998	Only USA	29 110	139	20.9%
[132] King et al. 1998	More than one continent	209 409	618	33.8%
[133] Arvanitis et al. 1997	North America	87 274	361	24.1%
[134] Beasley et al. 1997b	More than one continent	146 275	421	34.7%
[135] Peuskens et al. 1997b	More than one continent	72 129	201	35.8%
[136] Small et al. 1997	More than one continent	83 203	286	29.0%
[137] Tollefson et al. 1997	More than one continent	700 1295	1995	35.1%
[138] Tran et al. 1997	More than one continent	119 220	339	35.1%
[139] Beasley et al. 1996c	Only USA	42 110	152	27.6%
[140] Beasley et al. 1996d	Only USA	41 294	335	12.2%
[141] Blin et al. 1996	Europe	24 38	62	38.7%
[142] Borison et al. 1996	Not reported	11 98	109	10.1%
[143] Huttunen et al. 1995	Europe	51 47	98	52.0%
[144] Peuskens et al. 1995c	More than one continent	468 894	1362	34.4%
[145] Marder et al. 1994b	Only USA	48 340	388	12.4%
[146] Ceskova et al. 1993	Europe	17 45	62	27.4%
[147] Choinard et al. 1993	North America	39 96	135	28.9%
[148] Hoyberg et al. 1993	Europe	30 107	137	21.9%

References from included studies:

1. Kane, J.M.; Schooler, N.R.; Marcy, P.; Correll, C.U.; Achtyes, E.D.; Gibbons, R.D.; Robinson, D.G. Effect of Long-Acting Injectable Antipsychotics vs Usual Care on Time to First

Hospitalization in Early-Phase Schizophrenia: A Randomized Clinical Trial. *JAMA Psychiatry* **2020**, *77*, 1217–1224, doi:10.1001/jamapsychiatry.2020.2076.

2. Citrome, L.; Ota, A.; Nagamizu, K.; Perry, P.; Weiller, E.; Baker, R.A. The Effect of Brexpiprazole (OPC-34712) and Aripiprazole in Adult Patients with Acute Schizophrenia: Results from a Randomized, Exploratory Study. *Int. Clin. Psychopharmacol.* **2016**, *31*, 192–201, doi:10.1097/YIC.000000000000123.
3. Gureje, O.; Miles, W.; Keks, N.; Grainger, D.; Lambert, T.; McGrath, J.; Tran, P.; Catts, S.; Fraser, A.; Hustig, H.; et al. Olanzapine vs Risperidone in the Management of Schizophrenia: A Randomized Double-Blind Trial in Australia and New Zealand. *Schizophr. Res.* **2003**, *61*, 303–314, doi:10.1016/s0920-9964(02)00226-8.
4. Harvey, P.D.; Napolitano, J.A.; Mao, L.; Gharabawi, G. Comparative Effects of Risperidone and Olanzapine on Cognition in Elderly Patients with Schizophrenia or Schizoaffective Disorder. *Int. J. Geriatr. Psychiatry* **2003**, *18*, 820–829, doi:10.1002/gps.929.
5. Hertling, I.; Philipp, M.; Dvorak, A.; Glaser, T.; Mast, O.; Beneke, M.; Ramskogler, K.; Salatu-Zyhlarz, G.; Walter, H.; Lesch, O.M. Flupenthixol versus Risperidone: Subjective Quality of Life as an Important Factor for Compliance in Chronic Schizophrenic Patients. *Neuropsychobiology* **2003**, *47*, 37–46, doi:10.1159/000068874.
6. Kane, J.M.; Eerdekens, M.; Lindenmayer, J.-P.; Keith, S.J.; Lesem, M.; Karcher, K. Long-Acting Injectable Risperidone: Efficacy and Safety of the First Long-Acting Atypical Antipsychotic. *Am. J. Psychiatry* **2003**, *160*, 1125–1132, doi:10.1176/appi.ajp.160.6.1125.
7. Kasper, S.; Lerman, M.N.; McQuade, R.D.; Saha, A.; Carson, W.H.; Ali, M.; Archibald, D.; Ingenito, G.; Marcus, R.; Pigott, T. Efficacy and Safety of Aripiprazole vs. Haloperidol for Long-Term Maintenance Treatment Following Acute Relapse of Schizophrenia. *Int. J. Neuropsychopharmacol.* **2003**, *6*, 325–337, doi:10.1017/S1461145703003651.
8. Lieberman, J.A.; Tollefson, G.; Tohen, M.; Green, A.I.; Gur, R.E.; Kahn, R.; McEvoy, J.; Perkins, D.; Sharma, T.; Zipursky, R.; et al. Comparative Efficacy and Safety of Atypical and Conventional Antipsychotic Drugs in First-Episode Psychosis: A Randomized, Double-Blind Trial of Olanzapine versus Haloperidol. *Am. J. Psychiatry* **2003**, *160*, 1396–1404, doi:10.1176/appi.ajp.160.8.1396.
9. Pigott, T.A.; Carson, W.H.; Saha, A.R.; Torbeyns, A.F.; Stock, E.G.; Ingenito, G.G. Aripiprazole for the Prevention of Relapse in Stabilized Patients with Chronic Schizophrenia: A Placebo-Controlled 26-Week Study. *J. Clin. Psychiatry* **2003**, *64*, 1048–1056, doi:10.4088/jcp.v64n0910.
10. Potkin, S.G.; Saha, A.R.; Kujawa, M.J.; Carson, W.H.; Ali, M.; Stock, E.; Stringfellow, J.; Ingenito, G.; Marder, S.R. Aripiprazole, an Antipsychotic with a Novel Mechanism of Action, and Risperidone vs Placebo in Patients with Schizophrenia and Schizoaffective Disorder. *Arch. Gen. Psychiatry* **2003**, *60*, 681–690, doi:10.1001/archpsyc.60.7.681.
11. Ritchie, C.W.; Chiu, E.; Harrigan, S.; Hall, K.; Hassett, A.; Macfarlane, S.; Mastwyk, M.; O'Connor, D.W.; Opie, J.; Ames, D. The Impact upon Extra-Pyramidal Side Effects, Clinical Symptoms and Quality of Life of a Switch from Conventional to Atypical Antipsychotics (Risperidone or Olanzapine) in Elderly Patients with Schizophrenia. *Int. J. Geriatr. Psychiatry* **2003**, *18*, 432–440, doi:10.1002/gps.862.
12. Wright, P.; Meehan, K.; Birkett, M.; Lindborg, S.R.; Taylor, C.C.; Morris, P.; Breier, A. A Comparison of the Efficacy and Safety of Olanzapine versus Haloperidol during Transition from Intramuscular to Oral Therapy. *Clin. Ther.* **2003**, *25*, 1420–1428, doi:10.1016/s0149-2918(03)80129-7.
13. Gründer, G.; Heinze, M.; Cordes, J.; Mühlbauer, B.; Juckel, G.; Schulz, C.; Rüther, E.; Timm, J. Effects of First-Generation Antipsychotics versus Second-Generation Antipsychotics on Quality of Life in Schizophrenia: A Double-Blind, Randomised Study. *Lancet Psychiatry* **2016**, *3*, 717–729, doi:10.1016/S2215-0366(16)00085-7.
14. Arato, M.; O'Connor, R.; Meltzer, H.Y. A 1-Year, Double-Blind, Placebo-Controlled Trial of Ziprasidone 40, 80 and 160 Mg/Day in Chronic Schizophrenia: The Ziprasidone Extended Use in Schizophrenia (ZEUS) Study. *Int. Clin. Psychopharmacol.* **2002**, *17*, 207–215, doi:10.1097/00004850-200209000-00001.

15. Breier, A.; Meehan, K.; Birkett, M.; David, S.; Ferchland, I.; Sutton, V.; Taylor, C.C.; Palmer, R.; Dossenbach, M.; Kiesler, G.; et al. A Double-Blind, Placebo-Controlled Dose-Response Comparison of Intramuscular Olanzapine and Haloperidol in the Treatment of Acute Agitation in Schizophrenia. *Arch. Gen. Psychiatry* **2002**, *59*, 441–448, doi:10.1001/archpsyc.59.5.441.
16. Csernansky, J.G.; Mahmoud, R.; Brenner, R. A Comparison of Risperidone and Haloperidol for the Prevention of Relapse in Patients with Schizophrenia. *N. Engl. J. Med.* **2002**, *346*, 16–22, doi:10.1056/nejmoa002028.
17. Hirsch, S.R.; Kissling, W.; Bäuml, J.; Power, A.; O'Connor, R. A 28-Week Comparison of Ziprasidone and Haloperidol in Outpatients with Stable Schizophrenia. *J. Clin. Psychiatry* **2002**, *63*, 516–523, doi:10.4088/jcp.v63n0609.
18. Kane, J.M.; Carson, W.H.; Saha, A.R.; McQuade, R.D.; Ingenito, G.G.; Zimbroff, D.L.; Ali, M.W. Efficacy and Safety of Aripiprazole and Haloperidol versus Placebo in Patients with Schizophrenia and Schizoaffective Disorder. *J. Clin. Psychiatry* **2002**, *63*, 763–771, doi:10.4088/jcp.v63n0903.
19. Lee, C.-T.; Conde, B.J.L.; Mazlan, M.; Visanuyothin, T.; Wang, A.; Wong, M.M.C.; Walker, D.J.; Roychowdhury, S.M.; Wang, H.; Tran, P. V Switching to Olanzapine from Previous Antipsychotics: A Regional Collaborative Multicenter Trial Assessing 2 Switching Techniques in Asia Pacific. *J. Clin. Psychiatry* **2002**, *63*, 569–576, doi:10.4088/jcp.v63n0706.
20. Sechter, D.; Peuskens, J.; Fleurot, O.; Rein, W.; Lecrubier, Y. Amisulpride vs. Risperidone in Chronic Schizophrenia: Results of a 6-Month Double-Blind Study. *Neuropsychopharmacol. Off. Publ. Am. Coll. Neuropsychopharmacol.* **2002**, *27*, 1071–1081, doi:10.1016/S0893-133X(02)00375-5.
21. Conley, R.R.; Mahmoud, R. A Randomized Double-Blind Study of Risperidone and Olanzapine in the Treatment of Schizophrenia or Schizoaffective Disorder. *Am. J. Psychiatry* **2001**, *158*, 765–774, doi:10.1176/appi.ajp.158.5.765.
22. Daniel, D.G.; Potkin, S.G.; Reeves, K.R.; Swift, R.H.; Harrigan, E.P. Intramuscular (IM) Ziprasidone 20 Mg Is Effective in Reducing Acute Agitation Associated with Psychosis: A Double-Blind, Randomized Trial. *Psychopharmacology (Berl)* **2001**, *155*, 128–134, doi:10.1007/s002130000658.
23. Ishigooka, J.; Inada, T.; Miura, S. Olanzapine versus Haloperidol in the Treatment of Patients with Chronic Schizophrenia: Results of the Japan Multicenter, Double-Blind Olanzapine Trial. *Psychiatry Clin. Neurosci.* **2001**, *55*, 403–414, doi:10.1046/j.1440-1819.2001.00882.x.
24. Landbloom, R.; MacKle, M.; Wu, X.; Kelly, L.; Snow-Adami, L.; McIntyre, R.S.; Mathews, M.; Hundt, C. Asenapine for the Treatment of Adults with an Acute Exacerbation of Schizophrenia: Results from a Randomized, Double-Blind, Fixed-Dose, Placebo-Controlled Trial with Olanzapine as an Active Control. *CNS Spectr.* **2017**, *22*, 333–341, doi:10.1017/S1092852916000377.
25. Lesem, M.D.; Zajecka, J.M.; Swift, R.H.; Reeves, K.R.; Harrigan, E.P. Intramuscular Ziprasidone, 2 Mg versus 10 Mg, in the Short-Term Management of Agitated Psychotic Patients. *J. Clin. Psychiatry* **2001**, *62*, 12–18, doi:10.4088/jcp.v62n0104.
26. Bouchard, R.H.; Mérette, C.; Pourcher, E.; Demers, M.F.; Villeneuve, J.; Roy-Gagnon, M.H.; Gauthier, Y.; Cliche, D.; Labelle, A.; Filteau, M.J.; et al. Longitudinal Comparative Study of Risperidone and Conventional Neuroleptics for Treating Patients with Schizophrenia. The Quebec Schizophrenia Study Group. *J. Clin. Psychopharmacol.* **2000**, *20*, 295–304, doi:10.1097/00004714-200006000-00002.
27. Brook, S. A Pilot Study of Intramuscular Ziprasidone in the Short-Term Treatment of Patients with Acute Exacerbation of Schizophrenia. *Hum. Psychopharmacol.* **2000**, *15*, 521–524, doi:10.1002/1099-1077(200010)15:7<521::AID-HUP235>3.0.CO;2-V.
28. Copolov, D.L.; Link, C.G.; Kowalczyk, B. A Multicentre, Double-Blind, Randomized Comparison of Quetiapine (ICI 204,636, 'Seroquel') and Haloperidol in Schizophrenia. *Psychol. Med.* **2000**, *30*, 95–105, doi:10.1017/s0033291799001476.
29. Emsley, R.A.; Raniwalla, J.; Bailey, P.J.; Jones, A.M. A Comparison of the Effects of Quetiapine ('Seroquel') and Haloperidol in Schizophrenic Patients with a History of and a

Demonstrated, Partial Response to Conventional Antipsychotic Treatment. *Int. Clin. Psychopharmacol.* **2000**, *15*, 121–131, doi:10.1097/00004850-200015030-00001.

30. Heck, A.H.; Haffmans, P.M.J.; De Groot, I.W.; Hoencamp, E. Risperidone versus Haloperidol in Psychotic Patients with Disturbing Neuroleptic-Induced Extrapyrarnidal Symptoms: A Double-Blind, Multi-Center Trial. *Schizophr. Res.* **2000**, *46*, 97–105, doi:10.1016/S0920-9964(00)00009-8.
31. Purdon, S.E.; Jones, B.D.; Stip, E.; Labelle, A.; Addington, D.; David, S.R.; Breier, A.; Tollefson, G.D. Neuropsychological Change in Early Phase Schizophrenia during 12 Months of Treatment with Olanzapine, Risperidone, or Haloperidol. The Canadian Collaborative Group for Research in Schizophrenia. *Arch. Gen. Psychiatry* **2000**, *57*, 249–258, doi:10.1001/archpsyc.57.3.249.
32. Daniel, D.G.; Zimbroff, D.L.; Potkin, S.G.; Reeves, K.R.; Harrigan, E.P.; Lakshminarayanan, M. Ziprasidone 80 Mg/Day and 160 Mg/Day in the Acute Exacerbation of Schizophrenia and Schizoaffective Disorder: A 6-Week Placebo-Controlled Trial. Ziprasidone Study Group. *Neuropsychopharmacol. Off. Publ. Am. Coll. Neuropsychopharmacol.* **1999**, *20*, 491–505, doi:10.1016/S0893-133X(98)00090-6.
33. Emsley, R.A. Risperidone in the Treatment of First-Episode Psychotic Patients: A Double-Blind Multicenter Study. Risperidone Working Group. *Schizophr. Bull.* **1999**, *25*, 721–729, doi:10.1093/oxfordjournals.schbul.a033413.
34. Peuskens, J.; Bech, P.; Möller, H.J.; Bale, R.; Fleurot, O.; Rein, W. Amisulpride vs. Risperidone in the Treatment of Acute Exacerbations of Schizophrenia. *Psychiatry Res.* **1999**, *88*, 107–117, doi:10.1016/S0165-1781(99)00075-X.
35. Lieberman, J.A.; Davis, R.E.; Correll, C.U.; Goff, D.C.; Kane, J.M.; Tamminga, C.A.; Mates, S.; Vanover, K.E. ITI-007 for the Treatment of Schizophrenia: A 4-Week Randomized, Double-Blind, Controlled Trial. *Biol. Psychiatry* **2016**, *79*, 952–961, doi:10.1016/j.biopsych.2015.08.026.
36. Goff, D.C.; Posever, T.; Herz, L.; Simmons, J.; Kletti, N.; Lapierre, K.; Wilner, K.D.; Law, C.G.; Ko, G.N. An Exploratory Haloperidol-Controlled Dose-Finding Study of Ziprasidone in Hospitalized Patients with Schizophrenia or Schizoaffective Disorder. *J. Clin. Psychopharmacol.* **1998**, *18*, 296–304, doi:10.1097/00004714-199808000-00009.
37. Keck, P.J.; Buffenstein, A.; Ferguson, J.; Feighner, J.; Jaffe, W.; Harrigan, E.P.; Morrissey, M.R. Ziprasidone 40 and 120 Mg/Day in the Acute Exacerbation of Schizophrenia and Schizoaffective Disorder: A 4-Week Placebo-Controlled Trial. *Psychopharmacology (Berl)*. **1998**, *140*, 173–184, doi:10.1007/s002130050755.
38. King, D.J.; Link, C.G.; Kowalczyk, B. A Comparison of Bd and Tid Dose Regimens of Quetiapine (Seroquel) in the Treatment of Schizophrenia. *Psychopharmacology (Berl)* **1998**, *137*, 139–146, doi:10.1007/s002130050603.
39. Arvanitis, L.A.; Miller, B.G. Multiple Fixed Doses of “Seroquel” (Quetiapine) in Patients with Acute Exacerbation of Schizophrenia: A Comparison with Haloperidol and Placebo. The Seroquel Trial 13 Study Group. *Biol. Psychiatry* **1997**, *42*, 233–246, doi:10.1016/s0006-3223(97)00190-x.
40. Beasley, C.M.J.; Hamilton, S.H.; Crawford, A.M.; Dellva, M.A.; Tollefson, G.D.; Tran, P.V.; Blin, O.; Beuzen, J.N. Olanzapine versus Haloperidol: Acute Phase Results of the International Double-Blind Olanzapine Trial. *Eur. Neuropsychopharmacol. J. Eur. Coll. Neuropsychopharmacol.* **1997**, *7*, 125–137, doi:10.1016/s0924-977x(96)00392-6.
41. Peuskens, J.; Link, C.G. A Comparison of Quetiapine and Chlorpromazine in the Treatment of Schizophrenia. *Acta Psychiatr. Scand.* **1997**, *96*, 265–273, doi:10.1111/j.1600-0447.1997.tb10162.x.
42. Small, J.G.; Hirsch, S.R.; Arvanitis, L.A.; Miller, B.G.; Link, C.G. Quetiapine in Patients with Schizophrenia. A High- and Low-Dose Double-Blind Comparison with Placebo. Seroquel Study Group. *Arch. Gen. Psychiatry* **1997**, *54*, 549–557, doi:10.1001/archpsyc.1997.01830180067009.

43. Tollefson, G.D.; Beasley, C.M.J.; Tran, P.V.; Street, J.S.; Krueger, J.A.; Tamura, R.N.; Graffeo, K.A.; Thieme, M.E. Olanzapine versus Haloperidol in the Treatment of Schizophrenia and Schizoaffective and Schizophreniform Disorders: Results of an International Collaborative Trial. *Am. J. Psychiatry* **1997**, *154*, 457–465, doi:10.1176/ajp.154.4.457.
44. Tran, P.V.; Hamilton, S.H.; Kuntz, A.J.; Potvin, J.H.; Andersen, S.W.; Beasley, C.J.; Tollefson, G.D. Double-Blind Comparison of Olanzapine versus Risperidone in the Treatment of Schizophrenia and Other Psychotic Disorders. *J. Clin. Psychopharmacol.* **1997**, *17*, 407–418, doi:10.1097/00004714-199710000-00010.
45. Beasley, C.M.J.; Sanger, T.; Satterlee, W.; Tollefson, G.; Tran, P.; Hamilton, S. Olanzapine versus Placebo: Results of a Double-Blind, Fixed-Dose Olanzapine Trial. *Psychopharmacology (Berl)* **1996**, *124*, 159–167, doi:10.1007/BF02245617.
46. Litman, R.E.; Smith, M.A.; Doherty, J.J.; Cross, A.; Raines, S.; Gertsik, L.; Zukin, S.R. AZD8529, a Positive Allosteric Modulator at the MGluR2 Receptor, Does Not Improve Symptoms in Schizophrenia: A Proof of Principle Study. *Schizophr. Res.* **2016**, *172*, 152–157, doi:10.1016/j.schres.2016.02.001.
47. Beasley, C.M.J.; Tollefson, G.; Tran, P.; Satterlee, W.; Sanger, T.; Hamilton, S. Olanzapine versus Placebo and Haloperidol: Acute Phase Results of the North American Double-Blind Olanzapine Trial. *Neuropsychopharmacol. Off. Publ. Am. Coll. Neuropsychopharmacol.* **1996**, *14*, 111–123, doi:10.1016/0893-133X(95)00069-P.
48. Blin, O.; Azorin, J.M.; Bouhours, P. Antipsychotic and Anxiolytic Properties of Risperidone, Haloperidol, and Methotrimeprazine in Schizophrenic Patients. *J. Clin. Psychopharmacol.* **1996**, *16*, 38–44, doi:10.1097/00004714-199602000-00007.
49. Borison, R.L.; Arvanitis, L.A.; Miller, B.G. ICI 204,636, an Atypical Antipsychotic: Efficacy and Safety in a Multicenter, Placebo-Controlled Trial in Patients with Schizophrenia. U.S. SEROQUEL Study Group. *J. Clin. Psychopharmacol.* **1996**, *16*, 158–169, doi:10.1097/00004714-199604000-00008.
50. Huttunen, M.O.; Piepponen, T.; Rantanen, H.; Larmo, I.; Nyholm, R.; Raitasuo, V. Risperidone versus Zuclopenthixol in the Treatment of Acute Schizophrenic Episodes: A Double-Blind Parallel-Group Trial. *Acta Psychiatr. Scand.* **1995**, *91*, 271–277, doi:10.1111/j.1600-0447.1995.tb09781.x.
51. Peuskens, J. Risperidone in the Treatment of Patients with Chronic Schizophrenia: A Multi-National, Multi-Centre, Double-Blind, Parallel-Group Study versus Haloperidol. Risperidone Study Group. *Br. J. Psychiatry* **1995**, *166*, 712–733, doi:10.1192/bjp.166.6.712.
52. Marder, S.R.; Meibach, R.C. Risperidone in the Treatment of Schizophrenia. *Am. J. Psychiatry* **1994**, *151*, 825–835, doi:10.1176/ajp.151.6.825.
53. Cesková, E.; Svestka, J. Double-Blind Comparison of Risperidone and Haloperidol in Schizophrenic and Schizoaffective Psychoses. *Pharmacopsychiatry* **1993**, *26*, 121–124.
54. Chouinard, G.; Jones, B.; Remington, G.; Bloom, D.; Addington, D.; MacEwan, G.W.; Labelle, A.; Beauclair, L.; Arnott, W. A Canadian Multicenter Placebo-Controlled Study of Fixed Doses of Risperidone and Haloperidol in the Treatment of Chronic Schizophrenic Patients. *J. Clin. Psychopharmacol.* **1993**, *13*, 25–40.
55. Høyberg, O.J.; Fensbo, C.; Remvig, J.; Lingjaerde, O.; Sloth-Nielsen, M.; Salvesen, I. Risperidone versus Perphenazine in the Treatment of Chronic Schizophrenic Patients with Acute Exacerbations. *Acta Psychiatr. Scand.* **1993**, *88*, 395–402, doi:10.1111/j.1600-0447.1993.tb03480.x.
56. Malla, A.; Chue, P.; Jordan, G.; Stip, E.; Kocerginski, D.; Milliken, H.; Joseph, A.; Williams, R.; Adams, B.; Manchanda, R.; et al. An Exploratory, Open-Label, Randomized Trial Comparing Risperidone Long-Acting Injectabl with Oral Antipsychotic Medication in the Treatment of Early Psychosis. *Clin. Schizophr. Relat. Psychoses* **2016**, *9*, 198–208, doi:10.3371/CSRP.MACH.061213.
57. Nasser, A.F.; Henderson, D.C.; Fava, M.; Fudala, P.J.; Twumasi-Ankrah, P.; Kouassi, A.; Heidbreder, C. Efficacy, Safety, and Tolerability of RBP-7000 Once-Monthly Risperidone for the Treatment of Acute Schizophrenia: An 8-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study. *J. Clin. Psychopharmacol.* **2016**, *36*, 130–140, doi:10.1097/JCP.0000000000000479.

58. Parabiaghi, A.; Tettamanti, M.; D'Avanzo, B.; Barbato, A. Metabolic Syndrome and Drug Discontinuation in Schizophrenia: A Randomized Trial Comparing Aripiprazole Olanzapine and Haloperidol. *Acta Psychiatr. Scand.* **2016**, *133*, 63–75, doi:10.1111/acps.12468.
59. Buckley, P.F.; Schooler, N.R.; Goff, D.C.; Hsiao, J.; Kopelowicz, A.; Lauriello, J.; Manschreck, T.; Mendelowitz, A.J.; Miller, D.D.; Severe, J.B.; et al. Comparison of SGA Oral Medications and a Long-Acting Injectable SGA: The PROACTIVE Study. *Schizophr. Bull.* **2015**, *41*, 449–459, doi:10.1093/schbul/sbu067.
60. Ishigooka, J.; Nakamura, J.; Fujii, Y.; Iwata, N.; Kishimoto, T.; Iyo, M.; Uchimura, N.; Nishimura, R.; Shimizu, N. Efficacy and Safety of Aripiprazole Once-Monthly in Asian Patients with Schizophrenia: A Multicenter, Randomized, Double-Blind, Non-Inferiority Study versus Oral Aripiprazole. *Schizophr. Res.* **2015**, *161*, 421–428, doi:10.1016/j.schres.2014.12.013.
61. Cheng, Z.; Yuan, Y.; Han, X.; Yang, L.; Zeng, X.; Yang, F.; Lu, Z.; Wang, C.; Deng, H.; Zhao, J.; et al. Rates and Predictors of One-Year Antipsychotic Treatment Discontinuation in First-Episode Schizophrenia: Results from an Open-Label, Randomized, “Real World” Clinical Trial. *Psychiatry Res.* **2019**, *273*, 631–640, doi:10.1016/j.psychres.2019.01.068.
62. Meltzer, H.Y.; Risinger, R.; Nasrallah, H.A.; Du, Y.; Zummo, J.; Corey, L.; Bose, A.; Stankovic, S.; Silverman, B.L.; Ehrich, E.W. A Randomized, Double-Blind, Placebo-Controlled Trial of Aripiprazole Lauroxil in Acute Exacerbation of Schizophrenia. *J. Clin. Psychiatry* **2015**, *76*, 1085–1090, doi:10.4088/JCP.14m09741.
63. Moosavi, S.M.; Ahmadi, M.; Mojtahedi, D.; Yazdani, J.; Monajemi, M.B. Comparison of Quetiapine and Risperidone in Treatment of Acute Psychosis: A Double-Blind, Randomized-Controlled Study. *Glob. J. Health Sci.* **2015**, *7*, 359–363, doi:10.5539/gjhs.v7n5p359.
64. Naber, D.; Hansen, K.; Forray, C.; Baker, R.A.; Sapin, C.; Beillat, M.; Peters-Strickland, T.; Nylander, A.G.; Hertel, P.; Andersen, H.S.; et al. Qualify: A Randomized Head-to-Head Study of Aripiprazole Once-Monthly and Paliperidone Palmitate in the Treatment of Schizophrenia. *Schizophr. Res.* **2015**, *168*, 498–504, doi:10.1016/j.schres.2015.07.007.
65. Robinson, D.G.; Gallego, J.A.; John, M.; Petrides, G.; Hassoun, Y.; Zhang, J.P.; Lopez, L.; Braga, R.J.; Sevy, S.M.; Addington, J.; et al. A Randomized Comparison of Aripiprazole and Risperidone for the Acute Treatment of First-Episode Schizophrenia and Related Disorders: 3-Month Outcomes. *Schizophr. Bull.* **2015**, *41*, 1227–1236, doi:10.1093/schbul/sbv125.
66. Subotnik, K.L.; Casaus, L.R.; Ventura, J.; Luo, J.S.; Helleman, G.S.; Gretchen-Doorly, D.; Marder, S.; Nuechterlein, K.H. Long-Acting Injectable Risperidone for Relapse Prevention and Control of Breakthrough Symptoms after a Recent First Episode of Schizophrenia: A Randomized Clinical Trial. *JAMA Psychiatry* **2015**, *72*, 822–829, doi:10.1001/jamapsychiatry.2015.0270.
67. Tybura, P.; Trzeźniowska-Drukała, B.; Bienkowski, P.; Beszlej, A.; Frydecka, D.; Mierzejewski, P.; Samochowiec, A.; Grzywacz, A.; Samochowiec, J. Pharmacogenetics of Adverse Events in Schizophrenia Treatment: Comparison Study of Ziprasidone, Olanzapine and Perazine. *Psychiatry Res.* **2014**, *219*, 261–267, doi:10.1016/j.psychres.2014.05.039.
68. Durgam, S.; Starace, A.; Li, D.; Migliore, R.; Ruth, A.; Németh, G.; Laszlovszky, I. An Evaluation of the Safety and Efficacy of Cariprazine in Patients with Acute Exacerbation of Schizophrenia: A Phase II, Randomized Clinical Trial. *Schizophr. Res.* **2014**, *152*, 450–457, doi:10.1016/j.schres.2013.11.041.
69. Hatta, K.; Otachi, T.; Fujita, K.; Morikawa, F.; Ito, S.; Tomiyama, H.; Abe, T.; Sudo, Y.; Takebayashi, H.; Yamashita, T.; et al. Antipsychotic Switching versus Augmentation among Early Non-Responders to Risperidone or Olanzapine in Acute-Phase Schizophrenia. *Schizophr. Res.* **2014**, *158*, 213–222, doi:10.1016/j.schres.2014.07.015.
70. Li, H.; Luo, J.; Wang, C.; Xie, S.; Xu, X.; Wang, X.; Yu, W.; Gu, N.; Kane, J.M. Efficacy and Safety of Aripiprazole in Chinese Han Schizophrenia Subjects: A Randomized, Double-Blind, Active Parallel-Controlled, Multicenter Clinical Trial. *Schizophr. Res.* **2014**, *157*, 112–119, doi:10.1016/j.schres.2014.05.040.

71. Mirabzadeh, A.; Kimiaghali, P.; Fadai, F.; Samiei, M.; Daneshmand, R. The Therapeutic Effectiveness of Risperidone on Negative Symptoms of Schizophrenia in Comparison with Haloperidol: A Randomized Clinical Trial. *Basic Clin. Neurosci.* **2014**, *5*, 212–7.
72. Jena, M.; Ranjan, R.; Mishra, B.R.; Mishra, A.; Nath, S.; Sahu, P.; Meher, B.R.; Srinivasan, A.; Maiti, R. Effect of Lurasidone vs Olanzapine on Neurotrophic Biomarkers in Unmedicated Schizophrenia: A Randomized Controlled Trial. *J. Psychiatr. Res.* **2019**, *112*, 1–6, doi:10.1016/j.jpsychires.2019.02.007.
73. Shen, J.H.Q.; Zhao, Y.; Rosenzweig-Lipson, S.; Popp, D.; Williams, J.B.W.; Giller, E.; Detke, M.J.; Kane, J.M. A 6-Week Randomized, Double-Blind, Placebo-Controlled, Comparator Referenced Trial of Vabicaserin in Acute Schizophrenia. *J. Psychiatr. Res.* **2014**, *53*, 14–22, doi:10.1016/j.jpsychires.2014.02.012.
74. Shojia Shafti, S.; Gilanipoor, M. A Comparative Study between Olanzapine and Risperidone in the Management of Schizophrenia. *Schizophr. Res. Treat.* **2014**, *2014*, 1–5, doi:10.1155/2014/307202.
75. Amr, M.; Lakhan, S.E.; Sanhan, S.; Al-Rhaddad, D.; Hassan, M.; Thiab, M.; Shams, T. Efficacy and Tolerability of Quetiapine versus Haloperidol in First-Episode Schizophrenia: A Randomized Clinical Trial. *Int. Arch. Med.* **2013**, *6*, 1–8, doi:10.1186/1755-7682-6-47.
76. Wang, C.H.; Li, Y.; Yang, J.; Su, L.Y.; Geng, Y.G.; Li, H.; Wang, J.K.; Mu, J.L. A Randomized Controlled Trial of Olanzapine Improving Memory Deficits in Han Chinese Patients with First-Episode Schizophrenia. *Schizophr. Res.* **2013**, *144*, 129–135, doi:10.1016/j.schres.2012.12.021.
77. Chung, T.S.; Lung, F.W. Different Impacts of Aquaporin 4 and MAOA Allele Variation among Olanzapine, Risperidone, and Paliperidone in Schizophrenia. *J. Clin. Psychopharmacol.* **2012**, *32*, 394–397, doi:10.1097/JCP.0b013e31825370f4.
78. Jindal, K.C.; Singh, G.P.; Munjal, V. Aripiprazole versus Olanzapine in the Treatment of Schizophrenia: A Clinical Study from India. *Int. J. Psychiatry Clin. Pract.* **2013**, *17*, 21–29, doi:10.3109/13651501.2011.653376.
79. Kane, J.M.; Sanchez, R.; Perry, P.P.; Jin, N.; Johnson, B.R.; Forbes, R.A.; McQuade, R.D.; Carson, W.H.; Fleischacker, W.W. Aripiprazole Intramuscular Depot as Maintenance Treatment in Patients with Schizophrenia: A 52-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study. *J. Clin. Psychiatry* **2012**, *73*, 617–624, doi:10.4088/JCP.11m07530.
80. Kwon, J.S.; Mittoux, A.; Hwang, J.Y.; Ong, A.; Cai, Z.J.; Su, T.P. The Efficacy and Safety of 12 Weeks of Treatment with Sertindole or Olanzapine in Patients with Chronic Schizophrenia Who Did Not Respond Successfully to Their Previous Treatments: A Randomized, Double-Blind, Parallel-Group, Flexible-Dose Study. *Int. Clin. Psychopharmacol.* **2012**, *27*, 326–335, doi:10.1097/YIC.0b013e32835767a0.
81. Li, Y.; Li, H.; Liu, Y.; Yan, X.; Yue, Y.; Qian, M. Comparison of Quetiapine and Risperidone in Chinese Han Patients with Schizophrenia: Results of a Single-Blind, Randomized Study. *Curr. Med. Res. Opin.* **2012**, *28*, 1725–1732, doi:10.1185/03007995.2012.728524.
82. Pawar, G.R.; Phadnis, P.; Paliwal, A. Evaluation of Efficacy, Safety, and Cognitive Profile of Amisulpride Per Se and Its Comparison with Olanzapine in Newly Diagnosed Schizophrenic Patients in an 8-Week, Double-Blind, Single-Centre, Prospective Clinical Trial. *ISRN Psychiatry* **2012**, *2012*, 1–5, doi:10.5402/2012/703751.
83. Pu, Z.P.; Li, G.R.; Zou, Z.P.; Tao, F.; Hu, S.H. A Randomized, 8-Week Study of the Effects of Extended-Release Paliperidone and Olanzapine on Heart Rate Variability in Patients with Schizophrenia. *J. Clin. Psychopharmacol.* **2019**, *39*, 243–248, doi:10.1097/JCP.0000000000001023.
84. Witte, M.M.; Case, M.G.; Schuh, K.J.; Ascher-Svanum, H. Effects of Olanzapine Long-Acting Injection on Levels of Functioning among Acutely Ill Patients with Schizophrenia. *Curr. Med. Res. Opin.* **2012**, *28*, 315–323, doi:10.1185/03007995.2012.657300.
85. Grootens, K.P.; Van Veelen, N.M.J.; Peuskens, J.; Sabbe, B.G.C.; Thys, E.; Buitelaar, J.K.; Verkes, R.J.; Kahn, R.S. Ziprasidone vs Olanzapine in Recent-Onset Schizophrenia and Schizoaffective Disorder: Results of an 8-Week Double-Blind Randomized Controlled Trial. *Schizophr. Bull.* **2011**, *37*, 352–361, doi:10.1093/schbul/sbp037.

86. Harvey, P.D.; Ogasa, M.; Cucchiaro, J.; Loebel, A.; Keefe, R.S.E. Performance and Interview-Based Assessments of Cognitive Change in a Randomized, Double-Blind Comparison of Lurasidone vs. Ziprasidone. *Schizophr. Res.* **2011**, *127*, 188–194, doi:10.1016/j.schres.2011.01.004.
87. Li, H.; Rui, Q.; Ning, X.; Xu, H.; Gu, N. A Comparative Study of Paliperidone Palmitate and Risperidone Long-Acting Injectable Therapy in Schizophrenia. *Prog. Neuro-Psychopharmacol. Biol. Psychiatry* **2011**, *35*, 1002–1008, doi:10.1016/j.pnpbp.2011.02.001.
88. Meltzer, H.Y.; Cucchiaro, J.; Silva, R.; Ogasa, M.; Phillips, D.; Xu, J.; Kalali, A.H.; Schweizer, E.; Pikalov, A.; Loebel, A. Lurasidone in the Treatment of Schizophrenia: A Randomized, Double-Blind, Placebo- and Olanzapine-Controlled Study. *Am. J. Psychiatry* **2011**, *168*, 957–967, doi:10.1176/appi.ajp.2011.10060907.
89. Shah, S.; Joshi, D. Tolerability and Efficacy of Paliperidone ER Compared to Olanzapine in the Treatment of Schizophrenia: A Randomized, Double-Blind, Multicentric Trial. *Ind. Psychiatry J.* **2012**, *20*, 25, doi:10.4103/0972-6748.98411.
90. Xiang, Y.T.; Wang, C.Y.; Ungvari, G.S.; Kreyenbuhl, J.A.; Chiu, H.F.K.; Lai, K.Y.C.; Lee, E.H.M.; Bo, Q.J.; Dixon, L.B. Weight Changes and Their Associations with Demographic and Clinical Characteristics in Risperidone Maintenance Treatment for Schizophrenia. *Pharmacopsychiatry* **2011**, *44*, 135–141, doi:10.1055/s-0031-1277178.
91. Zhang, Shu; Bruce Parsons; Yu, Gu, N.; Ma Double-Blind Comparison of Ziprasidone and Risperidone in the Treatment of Chinese Patients with Acute Exacerbation of Schizophrenia. *Neuropsychiatr. Dis. Treat.* **2011**, *77*, doi:10.2147/ndt.s16664.
92. Bhowmick, S.; Hazra, A.; Ghosh, M. Amisulpride versus Olanzapine in the Treatment of Schizophrenia in Indian Patients: Randomized Controlled Trial. *Aust. N. Z. J. Psychiatry* **2010**, *44*, 237–242, doi:10.3109/00048670903487134.
93. Chen, E.Y.H.; Hui, C.L.M.; Lam, M.M.L.; Chiu, C.P.Y.; Law, C.W.; Chung, D.W.S.; Tso, S.; Pang, E.P.F.; Chan, K.T.; Wong, Y.C.; et al. Maintenance Treatment with Quetiapine versus Discontinuation after One Year of Treatment in Patients with Remitted First Episode Psychosis: Randomised Controlled Trial. *BMJ* **2010**, *341*, doi:10.1136/bmj.c4024.
94. Chen, Y.L.; Chen, K.P.; Chiu, C.C.; Tai, M.H.; Lung, F.W. Early Predictors of Poor Treatment Response in Patients with Schizophrenia Treated with Atypical Antipsychotics. *BMC Psychiatry* **2018**, *18*, 1–8, doi:10.1186/s12888-018-1950-1.
95. Gaebel, W.; Schreiner, A.; Bergmans, P.; De Arce, R.; Rouillon, F.; Cordes, J.; Eriksson, L.; Smeraldi, E. Relapse Prevention in Schizophrenia and Schizoaffective Disorder with Risperidone Long-Acting Injectable vs Quetiapine: Results of a Long-Term, Open-Label, Randomized Clinical Trial. *Neuropsychopharmacology* **2010**, *35*, 2367–2377, doi:10.1038/npp.2010.111.
96. Johnsen, E.; Kroken, R.A.; Wentzel-Larsen, T.; Jørgensen, H.A. Effectiveness of Second-Generation Antipsychotics: A Naturalistic, Randomized Comparison of Olanzapine, Quetiapine, Risperidone, and Ziprasidone. *BMC Psychiatry* **2010**, *10*, doi:10.1186/1471-244X-10-26.
97. MacFadden, W.; Ma, Y.W.; Thomas Haskins, J.; Bossie, C.A.; Alphs, L. A Prospective Study Comparing the Long-Term Effectiveness of Injectable Risperidone Long-Acting Therapy and Oral Aripiprazole in Patients with Schizophrenia. *Psychiatry (Edgemont)* **2010**, *7*, 23–31.
98. Pandina, G.; Lane, R.; Gopal, S.; Gassmann-Mayer, C.; Hough, D.; Remmerie, B.; Simpson, G. A Double-Blind Study of Paliperidone Palmitate and Risperidone Long-Acting Injectable in Adults with Schizophrenia. *Prog. Neuro-Psychopharmacol. Biol. Psychiatry* **2011**, *35*, 218–226, doi:10.1016/j.pnpbp.2010.11.008.
99. Roberts, D.L.; Penn, D.L.; Corrigan, P.; Lipkovich, I.; Kinon, B.; Black, R.A. Antipsychotic Medication and Social Cue Recognition in Chronic Schizophrenia. *Psychiatry Res.* **2010**, *178*, 46–50, doi:10.1016/j.psychres.2010.04.006.
100. Fleischhacker, W.W.; McQuade, R.D.; Marcus, R.N.; Archibald, D.; Swanink, R.; Carson, W.H. A Double-Blind, Randomized Comparative Study of Aripiprazole and Olanzapine in Patients with Schizophrenia. *Biol. Psychiatry* **2009**, *65*, 510–517, doi:10.1016/j.biopsych.2008.07.033.

101. Hatta, K.; Sato, K.; Hamakawa, H.; Takebayashi, H.; Kimura, N.; Ochi, S.; Sudo, Y.; Asukai, N.; Nakamura, H.; Usui, C.; et al. Effectiveness of Second-Generation Antipsychotics with Acute-Phase Schizophrenia. *Schizophr. Res.* **2009**, *113*, 49–55, doi:10.1016/j.schres.2009.05.030.
102. Lublin, H.; Haug, H.J.; Koponen, H.; Sigmundsson, T.; Kolb, S.A. Ziprasidone versus Olanzapine, Risperidone or Quetiapine in Patients with Chronic Schizophrenia: A 12-Week Open-Label, Multicentre Clinical Trial. *World J. Biol. Psychiatry* **2009**, *10*, 710–718, doi:10.1080/15622970802269589.
103. Oliveira, I.R.; Elkis, H.; Gattaz, W.F.; Chaves, A.C.; Sena, de E.P.; Souza, F.G. de M.; Campos, J.A.; Bueno, J.R.; Silva, J.A.C.; Louzã, M.R.; et al. Aripiprazole for Patients with Schizophrenia and Schizoaffective Disorder: An Open-Label, Randomized, Study versus Haloperidol. *CNS Spectr.* **2009**, *14*, 93–102, doi:10.1017/S1092852900000249.
104. Cutler, A.J.; Kalali, A.H.; Weiden, P.J.; Hamilton, J.; Wolfgang, C.D. Four-Week, Double-Blind, Placebo- and Ziprasidone-Controlled Trial of Iloperidone in Patients with Acute Exacerbations of Schizophrenia. *J. Clin. Psychopharmacol.* **2008**, *28*, 20–28, doi:10.1097/JCP.0b013e318169d4ce.
105. Gómez-Revuelta, M.; Pelayo-Terán, J.M.; Juncal-Ruiz, M.; Ortiz-García de la Foz, V.; Vázquez-Bourgon, J.; González-Pinto, A.; Crespo-Facorro, B. Long-Term Antipsychotic Effectiveness in First Episode of Psychosis: A 3-Year Follow-up Randomized Clinical Trial Comparing Aripiprazole, Quetiapine, and Ziprasidone. *Int. J. Neuropsychopharmacol.* **2018**, *21*, 1090–1101, doi:10.1093/ijnp/pyy082.
106. Jerrell, J.M.; Ramirez, P.M. Changes in Neuropsychological Functioning Following Treatment with Risperidone, Olanzapine, and Conventional Antipsychotic Medications. *Hum. Psychopharmacol. Clin. Exp.* **2008**, *23*, 595–604, doi:10.1002/hup.967.
107. Kahn, R.S.; Fleischhacker, W.W.; Boter, H.; Davidson, M.; Vergouwe, Y.; Keet, I.P.; Gheorghe, M.D.; Rybakowski, J.K.; Galderisi, S.; Libiger, J.; et al. Effectiveness of Antipsychotic Drugs in First-Episode Schizophrenia and Schizophreniform Disorder: An Open Randomised Clinical Trial. *Lancet* **2008**, *371*, 1085–1097, doi:10.1016/S0140-6736(08)60486-9.
108. Kolotkin, R.L.; Corey-Lisle, P.K.; Crosby, R.D.; Kan, H.J.; McQuade, R.D. Changes in Weight and Weight-Related Quality of Life in a Multicentre, Randomized Trial of Aripiprazole versus Standard of Care. *Eur. Psychiatry* **2008**, *23*, 561–566, doi:10.1016/j.eurpsy.2008.01.1421.
109. Nimwegen, L.J.; De Haan, L.; Van Beveren, N.J.M.; Van Der Helm, M.; Van Den Brink, W.; Linszen, D. Effect of Olanzapine and Risperidone on Subjective Well-Being and Craving for Cannabis in Patients with Schizophrenia or Related Disorders: A Double-Blind Randomized Controlled Trial. *Can. J. Psychiatry* **2008**, *53*, 400–405, doi:10.1177/070674370805300610.
110. Sacchetti, E.; Valsecchi, P.; Parrinello, G. A Randomized, Flexible-Dose, Quasi-Naturalistic Comparison of Quetiapine, Risperidone, and Olanzapine in the Short-Term Treatment of Schizophrenia: The QUERISOLA Trial. *Schizophr. Res.* **2008**, *98*, 55–65, doi:10.1016/j.schres.2007.09.011.
111. Safa, M.; Sadr, S.; Delfan, B.; Saki, M.; Javad Tarrahi, M. Metabolic Effects of Olanzapine and Risperidone in Patients with Psychotic Disorders. *Int. J. Psychiatry Clin. Pract.* **2008**, *12*, 299–302, doi:10.1080/13651500802155337.
112. Dossenbach, M.; Treuer, T.; Kryzhanovskaya, L.; Saylan, M.; Dominguez, S.; Huang, X. Olanzapine versus Chlorpromazine in the Treatment of Schizophrenia: A Pooled Analysis of Four 6-Week, Randomized, Open-Label Studies in the Middle East and North Africa. *J. Clin. Psychopharmacol.* **2007**, *27*, 329–337, doi:10.1097/JCP.0b013e3180ca83b1.
113. Goldberg, T.E.; Goldman, R.S.; Burdick, K.E.; Malhotra, A.K.; Lencz, T.; Patel, R.C.; Woerner, M.G.; Schooler, N.R.; Kane, J.M.; Robinson, D.G. Cognitive Improvement after Treatment with Second-Generation Antipsychotic Medications in First-Episode Schizophrenia: Is It a Practice Effect? *Arch. Gen. Psychiatry* **2007**, *64*, 1115–1122, doi:10.1001/archpsyc.64.10.1115.

114. Kane, J.M.; Canas, F.; Kramer, M.; Ford, L.; Gassmann-Mayer, C.; Lim, P.; Eerdekens, M. Treatment of Schizophrenia with Paliperidone Extended-Release Tablets: A 6-Week Placebo-Controlled Trial. *Schizophr. Res.* **2007**, *90*, 147–161, doi:10.1016/j.schres.2006.09.012.
115. Marder, S.R.; Kramer, M.; Ford, L.; Eerdekens, E.; Lim, P.; Eerdekens, M.; Lowy, A. Efficacy and Safety of Paliperidone Extended-Release Tablets: Results of a 6-Week, Randomized, Placebo-Controlled Study. *Biol. Psychiatry* **2007**, *62*, 1363–1370, doi:10.1016/j.biopsych.2007.01.017.
116. Schennach, R.; Riedel, M.; Spellmann, I.; Musil, R.; Obermeier, M.; Jäger, M.; Bottlender, R.; Schmauss, M.; Laux, G.; Möller, H.J. Comparing Schizophrenia Patients with a Predicted High/Low Risk of Nonresponse Receiving Treatment with Ziprasidone and Haloperidol: A Randomized-Controlled Study. *Pharmacopsychiatry* **2019**, *52*, 180–185, doi:10.1055/a-0669-9461.
117. McEvoy, J.P.; Daniel, D.G.; Carson, W.H.; McQuade, R.D.; Marcus, R.N. A Randomized, Double-Blind, Placebo-Controlled, Study of the Efficacy and Safety of Aripiprazole 10, 15 or 20 Mg/Day for the Treatment of Patients with Acute Exacerbations of Schizophrenia. *J. Psychiatr. Res.* **2007**, *41*, 895–905, doi:10.1016/j.jpsychires.2007.05.002.
118. Zimbroff, D.; Warrington, L.; Loebel, A.; Yang, R.; Siu, C. Comparison of Ziprasidone and Aripiprazole in Acutely Ill Patients with Schizophrenia or Schizoaffective Disorder: A Randomized, Double-Blind, 4-Week Study. *Int. Clin. Psychopharmacol.* **2007**, *22*, 363–370, doi:10.1097/YIC.0b013e32816f7779.
119. Azorin, J.M.; Strub, N.; Loft, H. A Double-Blind, Controlled Study of Sertindole versus Risperidone in the Treatment of Moderate-to-Severe Schizophrenia. *Int. Clin. Psychopharmacol.* **2006**, *21*, 49–56, doi:10.1097/01.yic.0000177020.26311.a7.
120. Cutler, A.J.; Marcus, R.N.; Hardy, S.A.; O'Donnell, A.; Carson, W.H.; McQuade, R.D. The Efficacy and Safety of Lower Doses of Aripiprazole for the Treatment of Patients with Acute Exacerbation of Schizophrenia. *CNS Spectr.* **2006**, *11*, 691–702, doi:10.1017/S1092852900014784.
121. Harvey, P.D. Improvement in Social Competence With Short-Term Atypical Antipsychotic Treatment: A Randomized, Double-Blind Comparison of Quetiapine Versus Risperidone for Social Competence, Social Cognition, and Neuropsychological Functioning. *Am. J. Psychiatry* **2006**, *163*, 1918, doi:10.1176/appi.ajp.163.11.1918.
122. Harvey, P.D. Neuropsychological Normalization With Long-Term Atypical Antipsychotic Treatment: Results of a Six-Month Randomized, Double-Blind Comparison of Ziprasidone vs. Olanzapine. *J. Neuropsychiatr.* **2006**, *18*, 54–63, doi:10.1176/appi.neuropsych.18.1.54.
123. Kinon, B.J.; Noordsy, D.L.; Liu-Seifert, H.; Gulliver, A.H.; Ascher-Svanum, H.; Kollack-Walker, S. Randomized, Double-Blind 6-Month Comparison of Olanzapine and Quetiapine in Patients with Schizophrenia or Schizoaffective Disorder with Prominent Negative Symptoms and Poor Functioning. *J. Clin. Psychopharmacol.* **2006**, *26*, 453–461, doi:10.1097/01.jcp.0000236658.16286.25.
124. Lecrubier, Y.; Quintin, P.; Bouhassira, M.; Perrin, E.; Lancrenon, S. The Treatment of Negative Symptoms and Deficit States of Chronic Schizophrenia: Olanzapine Compared to Amisulpride and Placebo in a 6-Month Double-Blind Controlled Clinical Trial. *Acta Psychiatr. Scand.* **2006**, *114*, 319–327, doi:10.1111/j.1600-0447.2006.00887.x.
125. McCue, R.E.; Waheed, R.; Urcuyo, L.; Orendain, G.; Joseph, M.D.; Charles, R.; Hasan, S.M. Comparative Effectiveness of Second-Generation Antipsychotics and Haloperidol in Acute Schizophrenia. *Br. J. Psychiatry* **2006**, *189*, 433–440, doi:10.1192/bjp.bp.105.019307.
126. Brook, S.; Walden, J.; Benattia, I.; Siu, C.O.; Romano, S.J. Ziprasidone and Haloperidol in the Treatment of Acute Exacerbation of Schizophrenia and Schizoaffective Disorder: Comparison of Intramuscular and Oral Formulations in a 6-Week, Randomized, Blinded-Assessment Study. *Psychopharmacology (Berl)* **2005**, *178*, 514–523, doi:10.1007/s00213-004-2082-5.

127. Huang, M.; Yu, L.; Pan, F.; Lu, S.; Hu, S.; Hu, J.; Chen, J.; Jin, P.; Qi, H.; Xu, Y. A Randomized, 13-Week Study Assessing the Efficacy and Metabolic Effects of Paliperidone Palmitate Injection and Olanzapine in First-Episode Schizophrenia Patients. *Prog. Neuro-Psychopharmacol. Biol. Psychiatry* **2018**, *81*, 122–130, doi:10.1016/j.pnpbp.2017.10.021.
128. Chue, P.; Eerdekens, M.; Augustyns, I.; Lachaux, B.; Molcan, P.; Eriksson, L.; Pretorius, H.; David, A.S. Comparative Efficacy and Safety of Long-Acting Risperidone and Risperidone Oral Tablets. *Eur. Neuropsychopharmacol. J. Eur. Coll. Neuropsychopharmacol.* **2005**, *15*, 111–117, doi:10.1016/j.euroneuro.2004.07.003.
129. Lieberman, J.A.; Scott Stroup, T.; McEvoy, J.P.; Swartz, M.S.; Rosenheck, R.A.; Perkins, D.O.; Keefe, R.S.E.; Davis, S.M.; Davis, C.E.; Lebowitz, B.D.; et al. Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia. *N. Engl. J. Med.* **2005**, *353*, 1209–1223, doi:10.1056/NEJMoa051688.
130. Schooler, N.; Rabinowitz, J.; Davidson, M.; Emsley, R.; Harvey, P.D.; Kopala, L.; McGorry, P.D.; Van Hove, I.; Eerdekens, M.; Swyzen, W.; et al. Risperidone and Haloperidol in First-Episode Psychosis: A Long-Term Randomized Trial. *Am. J. Psychiatry* **2005**, *162*, 947–953, doi:10.1176/appi.ajp.162.5.947.
131. Strakowski, S.M.; Johnson, J.L.; DelBello, M.P.; Hamer, R.M.; Green, A.I.; Tohen, M.; Lieberman, J.A.; Glick, I.; Patel, J.K.; Lieberman, J.; et al. Quality of Life during Treatment with Haloperidol or Olanzapine in the Year Following a First Psychotic Episode. *Schizophr. Res.* **2005**, *78*, 161–169, doi:10.1016/j.schres.2005.04.017.
132. Addington, D.E.N.; Pantelis, C.; Dineen, M.; Benattia, I.; Romano, S.J. Efficacy and Tolerability of Ziprasidone versus Risperidone in Patients with Acute Exacerbation of Schizophrenia or Schizoaffective Disorder: An 8-Week, Double-Blind, Multicenter Trial. *J. Clin. Psychiatry* **2004**, *65*, 1624–1633, doi:10.4088/jcp.v65n1207.
133. Appelberg, B.; Tuisku, K.; Joffe, G. Is It Worth While Changing Clinically Stable Schizophrenic Out-Patients with Mild to Moderate Residual Symptoms and/or Side Effects from Conventional to Atypical Antipsychotics? A Prospective, Randomised Study with Olanzapine. *Eur. Psychiatry* **2004**, *19*, 516–518, doi:10.1016/j.eurpsy.2004.06.035.
134. Corrigan, M.H.; Gallen, C.C.; Bonura, M.L.; Merchant, K.M. Effectiveness of the Selective D4 Antagonist Sonepiprazole in Schizophrenia: A Placebo-Controlled Trial. *Biol. Psychiatry* **2004**, *55*, 445–451, doi:10.1016/j.biopsych.2003.10.004.
135. Currier, G.W.; Chou, J.C.-Y.; Feifel, D.; Bossie, C.A.; Turkoz, I.; Mahmoud, R.A.; Gharabawi, G.M. Acute Treatment of Psychotic Agitation: A Randomized Comparison of Oral Treatment with Risperidone and Lorazepam versus Intramuscular Treatment with Haloperidol and Lorazepam. *J. Clin. Psychiatry* **2004**, *65*, 386–394.
136. Daniel, D.G.; Zimbroff, D.L.; Swift, R.H.; Harrigan, E.P. The Tolerability of Intramuscular Ziprasidone and Haloperidol Treatment and the Transition to Oral Therapy. *Int. Clin. Psychopharmacol.* **2004**, *19*, 9–15, doi:10.1097/00004850-200401000-00002.
137. Dossenbach, M.R.K.; Folnegovic-Smalc, V.; Hotujac, L.; Uglesic, B.; Tollefson, G.D.; Grundy, S.L.; Friedel, P.; Jakovljevic, M.M. Double-Blind, Randomized Comparison of Olanzapine versus Fluphenazine in the Long-Term Treatment of Schizophrenia. *Prog. Neuropsychopharmacol. Biol. Psychiatry* **2004**, *28*, 311–318, doi:10.1016/j.pnpbp.2003.10.010.
138. Ismail, Z.; Peters-Strickland, T.; Miguez, M.; Baker, R.A.; Hertel, P.; Eramo, A.; Jin, N.; Perry, P.; Sanchez, R.; McQuade, R.D.; et al. Aripiprazole Once-Monthly in the Treatment of Acute Psychotic Episodes in Schizophrenia: Post Hoc Analysis of Positive and Negative Syndrome Scale Marder Factor Scores. *J. Clin. Psychopharmacol.* **2017**, *37*, 347–350, doi:10.1097/JCP.0000000000000710.
139. Gaebel, W.; Möller, H.J.; Buchkremer, G.; Ohmann, C.; Riesbeck, M.; Wölwer, W.; Von Wilmsdorff, M.; Bottlender, R.; Klingberg, S. Pharmacological Long-Term Treatment Strategies in First Episode Schizophrenia: Study Design and Preliminary Results of an Ongoing RCT within the German Research Network on Schizophrenia. *Eur. Arch. Psychiatry Clin. Neurosci.* **2004**, *254*, 129–140, doi:10.1007/s00406-004-0509-y.
140. Harrigan, E.P.; Miceli, J.J.; Anziano, R.; Watsky, E.; Reeves, K.R.; Cutler, N.R.; Sramek, J.; Shiovitz, T.; Middle, M. A Randomized Evaluation of the Effects of Six Antipsychotic

- Agents on QTc, in the Absence and Presence of Metabolic Inhibition. *J. Clin. Psychopharmacol.* **2004**, 24, 62–69, doi:10.1097/01.jcp.0000104913.75206.62.
141. Kinon, B.J.; Ahl, J.; Rotelli, M.D.; McMullen, E. Efficacy of Accelerated Dose Titration of Olanzapine with Adjunctive Lorazepam to Treat Acute Agitation in Schizophrenia. *Am. J. Emerg. Med.* **2004**, 22, 181–186, doi:10.1016/j.ajem.2004.02.021.
 142. Knegtering, R.; Castelein, S.; Bous, H.; Van Der Linde, J.; Bruggeman, R.; Kluiters, H.; van den Bosch, R.J. A Randomized Open-Label Study of the Impact of Quetiapine versus Risperidone on Sexual Functioning. *J. Clin. Psychopharmacol.* **2004**, 24, 56–61, doi:10.1097/01.jcp.0000106220.36344.04.
 143. Mari, J.J.; Lima, M.S.; Costa, A.N.; Alexandrino, N.; Rodrigues-Filho, S.; de Oliveira, I.R.; Tollefson, G.D. The Prevalence of Tardive Dyskinesia after a Nine Month Naturalistic Randomized Trial Comparing Olanzapine with Conventional Treatment for Schizophrenia and Related Disorders. *Eur. Arch. Psychiatry Clin. Neurosci.* **2004**, 254, 356–361, doi:10.1007/s00406-004-0514-1.
 144. McQuade, R.D.; Stock, E.; Marcus, R.; Jody, D.; Gharbia, N.A.; Vanveggel, S.; Archibald, D.; Carson, W.H. A Comparison of Weight Change during Treatment with Olanzapine or Aripiprazole: Results from a Randomized, Double-Blind Study. *J. Clin. Psychiatry* **2004**, 65 (Suppl. 1), 47–56.
 145. Mortimer, A.; Martin, S.; L  o, H.; Peuskens, J. A Double-Blind, Randomized Comparative Trial of Amisulpride versus Olanzapine for 6 Months in the Treatment of Schizophrenia. *Int. Clin. Psychopharmacol.* **2004**, 19, 63–69, doi:10.1097/00004850-200403000-00002.
 146. Simpson, G.M.; Glick, I.D.; Weiden, P.J.; Romano, S.J.; Siu, C.O. Randomized, Controlled, Double-Blind Multicenter Comparison of the Efficacy and Tolerability of Ziprasidone and Olanzapine in Acutely Ill Inpatients with Schizophrenia or Schizoaffective Disorder. *Am. J. Psychiatry* **2004**, 161, 1837–1847, doi:10.1176/ajp.161.10.1837.
 147. Yamashita, H.; Mori, K.; Nagao, M.; Okamoto, Y.; Morinobu, S.; Yamawaki, S. Effects of Changing from Typical to Atypical Antipsychotic Drugs on Subjective Sleep Quality in Patients with Schizophrenia in a Japanese Population. *J. Clin. Psychiatry* **2004**, 65, 1525–1530, doi:10.4088/jcp.v65n1114.
 148. Beasley, C.M.J.; Sutton, V.K.; Hamilton, S.H.; Walker, D.J.; Dossenbach, M.; Taylor, C.C.; Alaka, K.J.; Bykowski, D.; Tollefson, G.D. A Double-Blind, Randomized, Placebo-Controlled Trial of Olanzapine in the Prevention of Psychotic Relapse. *J. Clin. Psychopharmacol.* **2003**, 23, 582–594, doi:10.1097/01.jcp.0000095348.32154.ec.

Table S2. Post hoc analysis/Multiple comparisons—Differences on proportion of women recruited according to trial characteristics.

	<i>Mean Difference (a–b)</i>	<i>Std. Error</i>	<i>Sig. (p-Value)</i>	<i>95% Confidence Interval</i>		
				<i>Lower Bound</i>	<i>Upper Bound</i>	
Decade of publication						
≤ 2000 vs. 2001–2010	–7.28% *	0.029	0.015	–0.131	–0.015	
≤ 2000 vs. ≥ 2011	–7.68% *	0.032	0.016	–0.139	–0.014	
2001–2010 vs. ≥ 2011	–0.40%	0.025	0.872	–0.053	0.045	
Funding						
Pharmaceutical vs. Non-pharmaceutical	–8.80% *	0.029	0.003	–0.144	–0.031	
Location						
North America vs. Asia	–19.44% *	0.030	<0.001	–0.254	–0.135	
North America vs. Europe	–13.72% *	0.032	<0.001	–0.200	–0.074	
North America vs. Other	–20.11% *	0.062	0.002	–0.324	–0.078	
North America vs. More than one continent	–8.80% *	0.027	0.001	–0.142	–0.034	
Asia vs. Europe	5.72%	0.033	0.086	–0.008	0.123	
Asia vs. Other	–0.66%	0.063	0.916	–0.131	0.118	
Asia vs. More than one continent	10.64% *	0.029	<0.001	0.050	0.163	
Europe vs. Other	–6.38%	0.064	0.318	–0.190	0.062	

	<i>Europe vs. More than one continent</i>	4.92%	0.030	0.109	-0.011	0.110
	<i>Other vs. More than one continent</i>	11.30%	0.061	0.068	-0.009	0.235
Inclusion criteria for women						
	<i>Yes vs. Not specified</i>	-6.10% *	0.022	0.021	-0.095	-0.008
Setting						
	<i>Inpatient vs. Outpatient</i>	-6.39% *	0.032	0.047	-0.127	-0.001
	<i>Inpatient vs. Both</i>	-6.86% *	0.028	0.015	-0.124	-0.013
	<i>Outpatient vs. Both</i>	-0.46%	0.035	0.894	-0.074	0.064
Use of olanzapine						
	<i>Yes vs. No</i>	6.10% *	0.022	0.005	0.018	0.104
Use of FGA						
	<i>Yes vs. No</i>	-5.00% *	0.023	0.033	-0.095	-0.004
Use of placebo						
	<i>Yes vs. No</i>	-8.60% *	0.025	0.001	-0.135	-0.037
Antipsychotic of interest						
	<i>Single SGA vs. Multiple SGAs</i>	-7.80% *	0.021	<0.001	-0.120	-0.036
Comparator arm						
	<i>FGA vs. Only SGAs</i>	-7.53% *	0.024	0.002	-0.124	-0.027
	<i>FGA vs. Placebo</i>	3.49%	0.033	0.299	-0.031	0.101
	<i>FGA vs. FGA + placebo</i>	4.98%	0.037	0.179	-0.023	0.123
	<i>Placebo vs. Only SGAs</i>	-11.02% *	0.032	0.001	-0.173	-0.048
	<i>Placebo vs. FGA + placebo</i>	1.49%	0.042	0.723	-0.068	0.098
	<i>FGA + placebo vs. Only SGAs</i>	-12.51% *	0.035	0.001	-0.195	-0.055

* The mean difference is significant at the 0.05 level. Multiple comparisons only performed for variables with $p < 0.05$ on ANOVA.

Table S3. PRISMA Checklist.

Section and Topic	Checklist Item	Where Item Is Reported
TITLE		
Title	1. Identify the report as a systematic review.	Page 1
ABSTRACT		
Abstract	2. See the PRISMA 2020 for Abstracts checklist.	Page 1
INTRODUCTION		
Rationale	3. Describe the rationale for the review in the context of existing knowledge.	Pages 1–3, evidence in context
Objectives	4. Provide an explicit statement of the objective(s) or question(s) the review addresses.	Lines 107–110
METHODS		
Eligibility criteria	5. Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses.	Item 2.2
Information sources	6. Specify all databases, registers, websites, organisations, reference lists and other sources searched or consulted to identify studies. Specify the date when each source was last searched or consulted.	Item 2.1
Search strategy	7. Present the full search strategies for all databases, registers and websites, including any filters and limits used.	Item 2.1
Selection process	8. Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers screened each record and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process.	Item 2.3

Data collection process	9. Specify the methods used to collect data from reports, including how many reviewers collected data from each report, whether they worked independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of automation tools used in the process.	Item 2.3
Data items	10a. List and define all outcomes for which data were sought. Specify whether all results that were compatible with each outcome domain in each study were sought (e.g., for all measures, time points, analyses), and if not, the methods used to decide which results to collect. 10b. List and define all other variables for which data were sought (e.g., participant and intervention characteristics, funding sources). Describe any assumptions made about any missing or unclear information.	Item 2.3
Study risk of bias assessment	11. Specify the methods used to assess risk of bias in the included studies, including details of the tool(s) used, how many reviewers assessed each study and whether they worked independently, and if applicable, details of automation tools used in the process.	Item 2.3
Effect measures	12. Specify for each outcome the effect measure(s) (e.g., risk ratio, mean difference) used in the synthesis or presentation of results.	NA
Synthesis methods	13a. Describe the processes used to decide which studies were eligible for each synthesis (e.g., tabulating the study intervention characteristics and comparing against the planned groups for each synthesis (item #5)).	Item 2.2
	13b. Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing summary statistics, or data conversions.	Item 2.4
	13c. Describe any methods used to tabulate or visually display results of individual studies and syntheses.	NA
	13d. Describe any methods used to synthesize results and provide a rationale for the choice(s). If meta-analysis was performed, describe the model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) used.	Item 2.4
	13e. Describe any methods used to explore possible causes of heterogeneity among study results (e.g., subgroup analysis, meta-regression).	Item 2.4
Reporting bias assessment	14. Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from reporting biases).	NA
Certainty assessment	15. Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome.	NA
RESULTS		
Study selection	16a. Describe the results of the search and selection process, from the number of records identified in the search to the number of studies included in the review, ideally using a flow diagram. 16b. Cite studies that might appear to meet the inclusion criteria, but which were excluded, and explain why they were excluded.	Figure 1 NA
Study characteristics	17. Cite each included study and present its characteristics.	Appendix A
Risk of bias in studies	18. Present assessments of risk of bias for each included study.	NA
Results of individual studies	19. For all outcomes, present, for each study: (a) summary statistics for each group (where appropriate) and (b) an effect estimate and its precision (e.g., confidence/credible interval), ideally using structured tables or plots. 20a. For each synthesis, briefly summarise the characteristics and risk of bias among contributing studies.	Appendix A, Table A1 Table 2
Results of syntheses	20b. Present results of all statistical syntheses conducted. If meta-analysis was done, present for each the summary estimate and its precision (e.g., confidence/credible interval) and measures of statistical heterogeneity. If comparing groups, describe the direction of the effect.	Tables 2–4

	20c. Present results of all investigations of possible causes of heterogeneity among study results.	NA
	20d. Present results of all sensitivity analyses conducted to assess the robustness of the synthesized results.	NA
Reporting biases	21. Present assessments of risk of bias due to missing results (arising from reporting biases) for each synthesis assessed.	NA
Certainty of evidence	22. Present assessments of certainty (or confidence) in the body of evidence for each outcome assessed.	NA
DISCUSSION		
	23a. Provide a general interpretation of the results in the context of other evidence.	Lines 254–292
	23b. Discuss any limitations of the evidence included in the review.	Lines 332–346
Discussion	23c. Discuss any limitations of the review processes used.	Lines 332–346
	23d. Discuss implications of the results for practice, policy, and future research.	Lines 347–367
OTHER INFORMATION		
	24a. Provide registration information for the review, including register name and registration number, or state that the review was not registered.	Not registered
Registration and protocol	24b. Indicate where the review protocol can be accessed, or state that a protocol was not prepared.	Item 2.1
	24c. Describe and explain any amendments to information provided at registration or in the protocol.	NA
Support	25. Describe sources of financial or non-financial support for the review, and the role of the funders or sponsors in the review.	Line 373–374
Competing interests	26. Declare any competing interests of review authors.	Line 375
Availability of other materials	27. Report which of the following are publicly available and where they can be found: template data collection forms; data extracted from included studies; data used for all analyses; analytic code; any other materials used in the review.	NA

From: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ* 2021;372:n71. doi: 10.1136/bmj.n71.